+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
ID05054257

Phase I Study of CART19 Cells for Adults with Relapsed or Refractory CD19 Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Led by Institute of Hematology and Blood Transfusion, Czech Republic · Updated on 2025-01-06

10

Participants Needed

1

Research Sites

27 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and appropriate dosing of CART19 cells in adult patients with relapsed or refractory CD19-positive B-cell Acute Lymphoblastic Leukemia B-ALL or Non-Hodgkins Lymphoma NHL. This Phase I, open-label, single-arm study aims to find the maximum tolerated or feasible dose of these engineered T cells, which are designed to target cancer cells. Up to 24 adults with these conditions will participate to understand the treatments effects and potential risks. Participants will first undergo a lymphodepleting conditioning regimen to prepare their immune system. They will then receive a single dose of autologous CAR19 T lymphocytes, which are made from their own cells and modified to recognize CD19 on cancer cells. The dose of CART19 will be increased stepwise in consecutive patients to establish the recommended dose for future studies. This dosing approach continues until either the maximum tolerated dose or maximum feasible dose is identified. During the study, patients will be closely monitored for adverse events and dose-limiting toxicities up to 28 days after receiving the treatment and for up to two years thereafter. Researchers will also assess complete remission rates at 100 days and 6 months, overall survival at one year, and quality of life using a cancer-specific questionnaire at 6 months and one year. The study includes extensive evaluations, including imaging, laboratory tests, and quality-of-life assessments to track the patients status throughout the trial and follow-up period.

CONDITIONS

Brief Title

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Research Team

J

Jan Vydra

P

Petr Lesny

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here